FI104949B - Menetelmä säädellysti budesonidia vapauttavan oraalisesti annettavan koostumuksen valmistamiseksi - Google Patents

Menetelmä säädellysti budesonidia vapauttavan oraalisesti annettavan koostumuksen valmistamiseksi Download PDF

Info

Publication number
FI104949B
FI104949B FI922325A FI922325A FI104949B FI 104949 B FI104949 B FI 104949B FI 922325 A FI922325 A FI 922325A FI 922325 A FI922325 A FI 922325A FI 104949 B FI104949 B FI 104949B
Authority
FI
Finland
Prior art keywords
budesonide
epimer
water
hours
polymer
Prior art date
Application number
FI922325A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI922325A0 (fi
FI922325L (fi
Inventor
Jan Ulmius
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI104949(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Draco Ab filed Critical Draco Ab
Publication of FI922325A0 publication Critical patent/FI922325A0/fi
Publication of FI922325L publication Critical patent/FI922325L/fi
Application granted granted Critical
Publication of FI104949B publication Critical patent/FI104949B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
FI922325A 1989-11-22 1992-05-21 Menetelmä säädellysti budesonidia vapauttavan oraalisesti annettavan koostumuksen valmistamiseksi FI104949B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8903914A SE8903914D0 (sv) 1989-11-22 1989-11-22 Oral composition for the treatment of inflammatory bowel diseases
PCT/SE1990/000738 WO1991007172A1 (en) 1989-11-22 1990-11-15 Oral composition for the treatment of inflammatory bowel diseases
SE9000738 1990-11-15
SE8903914 1990-11-15

Publications (3)

Publication Number Publication Date
FI922325A0 FI922325A0 (fi) 1992-05-21
FI922325L FI922325L (fi) 1992-05-21
FI104949B true FI104949B (fi) 2000-05-15

Family

ID=20377544

Family Applications (2)

Application Number Title Priority Date Filing Date
FI922325A FI104949B (fi) 1989-11-22 1992-05-21 Menetelmä säädellysti budesonidia vapauttavan oraalisesti annettavan koostumuksen valmistamiseksi
FI19991893A FI19991893A7 (fi) 1989-11-22 1999-09-06 Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI19991893A FI19991893A7 (fi) 1989-11-22 1999-09-06 Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö

Country Status (36)

Country Link
US (1) US6423340B1 (cs)
EP (1) EP0502092B1 (cs)
JP (1) JP3145111B2 (cs)
KR (1) KR0179042B1 (cs)
AT (1) ATE125445T1 (cs)
AU (1) AU643021B2 (cs)
CA (1) CA2071518C (cs)
DE (1) DE69021214T2 (cs)
DK (1) DK0502092T3 (cs)
EG (1) EG19642A (cs)
ES (1) ES2074698T3 (cs)
FI (2) FI104949B (cs)
GR (1) GR3017691T3 (cs)
HK (1) HK51897A (cs)
HR (1) HRP920632B1 (cs)
HU (2) HU216836B (cs)
IE (1) IE74854B1 (cs)
IL (1) IL96415A (cs)
IS (1) IS1858B (cs)
LT (1) LT3696B (cs)
LV (1) LV10183B (cs)
MY (1) MY104535A (cs)
NO (1) NO304010B1 (cs)
NZ (1) NZ235807A (cs)
PL (1) PL166506B1 (cs)
PT (1) PT95946A (cs)
RU (1) RU2134104C1 (cs)
SA (1) SA90110123B1 (cs)
SE (1) SE8903914D0 (cs)
SG (1) SG54210A1 (cs)
SI (1) SI9012150A (cs)
TW (1) TW250435B (cs)
UA (1) UA37196C2 (cs)
WO (1) WO1991007172A1 (cs)
YU (1) YU48583B (cs)
ZA (1) ZA908777B (cs)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
BR9307746A (pt) * 1993-01-08 1995-11-14 Astra Ab Derivados de esteróides especificos para otratamento de cólon e ileo
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
WO1998022095A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
SE9902673D0 (sv) * 1999-07-12 1999-07-12 Astra Ab New composition
EP1392321B1 (en) * 2001-03-15 2010-08-18 Soligenix, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
DE60323138D1 (de) 2002-12-12 2008-10-02 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
WO2004087109A1 (ja) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
CA2538202C (en) * 2003-09-15 2013-01-15 Altana Pharma Ag Use of ciclesonide for the treatment of inflammatory bowel diseases
PT1670482E (pt) 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20070243184A1 (en) * 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
EP2143424A4 (en) * 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
BRPI0818286A2 (pt) * 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
CN102238868A (zh) * 2008-10-03 2011-11-09 福尔克博士药物有限责任公司 使用颗粒状5-氨基水杨酸治疗肠病的组合物和方法
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945615B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
JP2014504650A (ja) * 2011-02-04 2014-02-24 オプティマー ファーマシューティカルズ，インコーポレーテッド 細菌感染の治療
MD480Z (ro) * 2011-07-07 2012-09-30 Elvira Andon Metoda de tratament al colitei ulceroase nespecifice acute
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
EA032504B1 (ru) 2013-10-29 2019-06-28 Тиллоттс Фарма АГ Лекарственный препарат с отсроченным высвобождением и его применение для доставки лекарственного средства
WO2017042835A1 (en) * 2015-09-11 2017-03-16 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical dosage forms of budesonide
CN105663091A (zh) * 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
ES2874669T3 (es) * 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
RU2750937C2 (ru) * 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996356A (en) 1969-07-02 1976-12-07 Hoffmann-La Roche Inc. Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
SE378109B (cs) 1972-05-19 1975-08-18 Bofors Ab
SE7813246L (sv) 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8008524L (sv) 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8306370D0 (sv) 1983-11-18 1983-11-18 Draco Ab Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
US4708867A (en) 1983-12-19 1987-11-24 Key Pharmaceuticals, Inc. Minipellets
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
DE3536267A1 (de) 1985-10-11 1987-04-16 Bayer Ag Azofarbstoffe sowie fluessigkristallines material enthaltend azofarbstoffe
SE8506015D0 (sv) 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE10307386A1 (de) 2003-02-21 2004-09-09 Dieter Wildfang Gmbh Verfahren zum außenseitigen Beschichten eines sanitären Auslaufteiles sowie sanitäres Auslaufteil

Also Published As

Publication number Publication date
IL96415A (en) 1995-11-27
SA90110123B1 (ar) 1999-06-06
DE69021214T2 (de) 1996-01-04
TW250435B (cs) 1995-07-01
IL96415A0 (en) 1991-08-16
NO922004L (no) 1992-05-21
IS1858B (is) 2003-03-27
SE8903914D0 (sv) 1989-11-22
YU215090A (sr) 1996-01-09
HUT60630A (en) 1992-10-28
HRP920632B1 (en) 1999-10-31
JPH05501705A (ja) 1993-04-02
NO304010B1 (no) 1998-10-12
LV10183A (lv) 1994-10-20
HRP920632A2 (en) 1995-04-30
ATE125445T1 (de) 1995-08-15
UA37196C2 (uk) 2001-05-15
NO922004D0 (no) 1992-05-21
NZ235807A (en) 1993-02-25
LV10183B (en) 1995-08-20
ZA908777B (en) 1991-07-31
CA2071518C (en) 2002-11-12
EG19642A (en) 1995-08-30
FI922325A0 (fi) 1992-05-21
EP0502092B1 (en) 1995-07-26
FI922325L (fi) 1992-05-21
HK51897A (en) 1997-05-02
GR3017691T3 (en) 1996-01-31
IE74854B1 (en) 1997-08-13
KR920703025A (ko) 1992-12-17
IE904170A1 (en) 1991-05-22
HU9201700D0 (en) 1992-08-28
HU216836B (hu) 1999-09-28
AU7786491A (en) 1991-06-13
AU643021B2 (en) 1993-11-04
IS3644A7 (is) 1991-05-23
ES2074698T3 (es) 1995-09-16
RU2134104C1 (ru) 1999-08-10
EP0502092A1 (en) 1992-09-09
YU48583B (sh) 1998-12-23
DK0502092T3 (da) 1995-12-27
US6423340B1 (en) 2002-07-23
DE69021214D1 (de) 1995-08-31
FI19991893L (fi) 1999-09-06
WO1991007172A1 (en) 1991-05-30
CA2071518A1 (en) 1991-05-23
LT3696B (en) 1996-02-26
JP3145111B2 (ja) 2001-03-12
SG54210A1 (en) 1998-11-16
KR0179042B1 (ko) 1999-03-20
PT95946A (pt) 1991-09-13
PL287844A1 (en) 1991-12-02
SI9012150A (sl) 1998-08-31
LTIP1751A (en) 1995-07-25
FI19991893A7 (fi) 1999-09-06
PL166506B1 (pl) 1995-05-31
MY104535A (en) 1994-04-30

Similar Documents

Publication Publication Date Title
FI104949B (fi) Menetelmä säädellysti budesonidia vapauttavan oraalisesti annettavan koostumuksen valmistamiseksi
US5643602A (en) Oral composition for the treatment of inflammatory bowel disease
CN101686948B (zh) 环孢菌素药物组合物
DE60131703T2 (de) Orale feste pharmazeutische Zusammensetzungen mit pH-abhängiger Mehrphasen- Freisetzung
JP3194974B2 (ja) 標的制御釈放薬剤
JP3902229B2 (ja) 結腸デリバリー用の、多腸溶ポリマー被覆物を有する医薬投与形態
JPH05506022A (ja) 腸管への薬物放出のための投与形態物
EP1117387A2 (de) Überzogene arzneiformen mit kontrollierter wirkstoffabgabe
JPH09501939A (ja) クローン病および潰瘍性大腸炎の標的処置のための医薬組成物
WO2015018344A1 (zh) 穿心莲内酯在制备炎症性肠病的药物中的应用、穿心莲内酯肠溶靶向微丸及其制备方法
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
US20060057200A1 (en) Tablets with site- and time-controlled gastrointestinal release of active ingredient
CN112315934A (zh) 白头翁皂苷b4肠溶片的制备工艺
Ronchi et al. Development and evaluation of budesonide-based modified-release liquid oral dosage forms
JP5371189B2 (ja) 炎症性腸疾患の治療のためのシクレソニドの使用
CN112494461A (zh) 一种美沙拉嗪肠溶缓释药物组合物及制备方法
DE10013030A1 (de) Verwendung eines Copolymers zur Herstellung einer Arzneiform zur Therapie von Colitis ulcerosa und verwendungsgemäße Arzneiform
EP1100481B1 (en) Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease
CN103505422A (zh) 一种增溶大黄素含药丸芯、结肠靶向微丸及其制备方法
EA042135B1 (ru) Таблетка деферипрона с отсроченным высвобождением и способ ее изготовления